Skip to main content
ERYTECH Pharma S.A. logo

ERYTECH Pharma S.A. — Investor Relations & Filings

Ticker · ERYP ISIN · FR001400K4B1 LEI · 969500U8ZZCODU8A9374 PA Manufacturing
Open in API
Filings indexed 864 across all filing types
Latest filing 2023-05-24 AGM Information
Country FR France
Listing PA ERYP

About ERYTECH Pharma S.A.

https://phaxiam.com/

ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company that develops innovative therapeutics based on its proprietary ERYCAPS platform, which encapsulates drug substances inside red blood cells. This technology is designed to improve the efficacy and safety of treatments by prolonging the drug's circulation time and reducing side effects. The company's primary focus is on developing treatments for severe forms of cancer and orphan diseases. Its lead product candidate, eryaspase, encapsulates the enzyme L-asparaginase to starve cancer cells of essential nutrients, targeting indications such as acute lymphoblastic leukemia and pancreatic cancer.

Recent filings

Filing Released Lang Actions
ERYTECH annonce les modalités de mise à disposition des documents préparatoires à l’Assemblée Générale Mixte du 23 juin 2023
AGM Information Classification · 1% confidence The document is titled 'ERYTECH annonce les modalités de mise à disposition des documents préparatoires à l'Assemblée Générale Mixte du 23 juin 2023' (ERYTECH announces the terms for making available the preparatory documents for the Combined General Meeting of June 23, 2023). It explicitly discusses the logistics, dates, and availability of documents related to an upcoming Annual General Meeting (AGM). Although it mentions the availability of AGM documents, the primary focus is the announcement *about* the meeting and its preparatory materials, rather than the final voting results (DVA) or the definitive proxy statement (PSI). Since it concerns the AGM and the announcement of related materials, the most fitting category is AGM Information (AGM-R), as it details the meeting modalities and document availability. Given the short length (under 5,000 characters) and the nature of announcing the availability of other documents, it could also be considered an RPA, but the specific subject matter (AGM) makes AGM-R more precise.
2023-05-24 French
ERYTECH annonce la mise à disposition du document d'exemption relatif au projet de rapprochement avec Pherecydes
Report Publication Announcement Classification · 1% confidence The document is very short (2367 characters) and its primary purpose is to announce that a specific document, the 'document d'exemption relatif au projet de rapprochement avec Pherecydes' (exemption document related to the merger project with Pherecydes), has been published and is available on the company's website. This fits the definition of a Report Publication Announcement (RPA), which covers announcements regarding the timing, release, or publication of company reports, rather than being the report itself. The mention of a 'rapprochement' (merger/takeover) suggests a link to M&A activity (TAR), but the document's function here is purely to announce the availability of a related document, making RPA the most accurate classification based on the 'MENU VS MEAL' rule.
2023-05-23 French
ERYTECH announces the availability of the exemption document relating to the proposed combination with Pherecydes
Report Publication Announcement Classification · 1% confidence The document is very short (2428 characters) and its primary purpose, as stated in the headline, is to announce that ERYTECH has 'published the exemption document relating to the proposed combination with Pherecydes' and directs the reader to the company website to consult it. This fits the definition of a Report Publication Announcement (RPA), which covers announcements regarding the timing, release, or publication of company reports, rather than being the report itself. The content is an announcement, not the detailed M&A document (TAR) or a general regulatory filing (RNS).
2023-05-23 English
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 15 mai 2023
Share Issue/Capital Change Classification · 1% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social au 15 mai 2023" (Monthly information relating to the total number of voting rights and shares comprising the share capital as of May 15, 2023). It explicitly references Article 223-16 of the General Regulation of the Autorité des Marchés Financiers (AMF), which mandates monthly disclosure of total voting rights and shares outstanding. This content directly corresponds to reporting changes in the capital structure or share count, which is covered by the 'Share Issue/Capital Change' definition (SHA). Although it is a monthly update, the core subject matter is the capital structure, making SHA the most precise fit over a general 'Regulatory Filing' (RNS).
2023-05-16 French
Monthly information related to total number of voting rights and shares composing the share capital _May 15, 2023
Regulatory Filings Classification · 1% confidence The document is titled "Monthly information related to total number of voting rights and shares composing the share capital - May 15, 2023." It explicitly references Article 223-16 of the French AMF general regulation and provides a table detailing the evolution of the total number of shares and voting rights over several months, culminating in the May 15, 2023 figure. This type of regular disclosure concerning the total share capital and voting rights is a specific regulatory requirement, often falling under general regulatory announcements or specific capital structure updates. Since there is no specific code for 'Total Voting Rights Disclosure,' and it is a mandatory regulatory filing providing key structural data, it best fits the general 'Regulatory Filings' (RNS) category, as it is not an earnings release (ER), capital change announcement (CAP/SHA), or director dealing report (DIRS). It is a recurring, mandatory disclosure.
2023-05-16 English
ERYTECH Provides Update on the Announced Combination with PHERECYDES
M&A Activity Classification · 1% confidence The document is a press release dated May 15, 2023, providing an update on the announced combination (merger) between ERYTECH and PHERECYDES. It details the entry into a definitive merger agreement, the completion of a contribution in kind, and the upcoming shareholder vote scheduled for June 23, 2023. It also discusses board appointments and requests for an ad hoc agent for the general meeting. Since the document is an update and announcement regarding a significant corporate transaction (merger/takeover activity) and the subsequent governance/shareholder actions required for it, it strongly aligns with the definition of M&A Activity (TAR). While it mentions the upcoming shareholder vote (AGM/DVA context), the primary focus is the merger transaction itself.
2023-05-15 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.